Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Clinical development times for innovative drugs

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 793-794 (2022)



The views and opinions presented here represent those of the authors and should not be considered to represent advice or guidance on behalf of the US Food and Drug Administration.

Supplementary Information

  1. Supplementary Box 1
  2. Supplementary Table 1

Competing Interests

D.G.B. and H.J.W. are employees of Jnana Therapeutics, which does not have a direct bearing on the subject of this paper. H.J.W is a shareholder in AstraZeneca. The other authors declare no competing interests. This study was supported in part by the Intramural Research Program of the NCATS, NIH.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links